These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 11328624)

  • 1. Current treatment of Cutaneous T-Cell Lymphoma.
    Duvic M
    Dermatol Online J; 2001 Feb; 7(1):3. PubMed ID: 11328624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma.
    Querfeld C; Rosen ST; Guitart J; Rademaker A; Fung BB; Posten W; Kuzel TM
    J Am Acad Dermatol; 2004 Jul; 51(1):25-32. PubMed ID: 15243520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.
    Duvic M; Martin AG; Kim Y; Olsen E; Wood GS; Crowley CA; Yocum RC;
    Arch Dermatol; 2001 May; 137(5):581-93. PubMed ID: 11346336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topical and oral bexarotene.
    Schadt CR
    Dermatol Ther; 2013; 26(5):400-3. PubMed ID: 24099070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination treatment modalities in cutaneous T-cell lymphoma (CTCL).
    Guitart J
    Semin Oncol; 2006 Feb; 33(1 Suppl 3):S17-20. PubMed ID: 16516671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bexarotene (Targretin) for cutaneous T-cell lymphoma.
    Med Lett Drugs Ther; 2000 Apr; 42(1075):31-2. PubMed ID: 10788961
    [No Abstract]   [Full Text] [Related]  

  • 7. Development of Hodgkin's lymphoma under bexarotene treatment for Sézary syndrome and review of the literature.
    Sanli H; Akay BN; Ozcan M
    J Drugs Dermatol; 2010 Aug; 9(8):1014-6. PubMed ID: 20684154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series.
    Singh F; Lebwohl MG
    J Am Acad Dermatol; 2004 Oct; 51(4):570-3. PubMed ID: 15389192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bexarotene gel: a new skin-directed treatment option for cutaneous T-cell lymphomas.
    Martin AG
    J Drugs Dermatol; 2003 Apr; 2(2):155-67. PubMed ID: 12852367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of bexarotene in the treatment of cutaneous T-cell lymphoma: the clinical and immunological sides.
    Pileri A; Delfino C; Grandi V; Pimpinelli N
    Immunotherapy; 2013 Apr; 5(4):427-33. PubMed ID: 23557425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous T-cell lymphoma.
    Gilyon K; Kuzel TM
    Oncol Nurs Forum; 1991 Jul; 18(5):901-8. PubMed ID: 1891419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective study of cutaneous intolerance to topical mechlorethamine therapy in patients with cutaneous T-cell lymphomas. French Study Group of Cutaneous Lymphomas.
    Estève E; Bagot M; Joly P; Souteyrand P; Beylot-Barry M; Vaillant L; Delaunay M; Avril MF; Laroche L; Grange F; Thomine E; Wechsler J
    Arch Dermatol; 1999 Nov; 135(11):1349-53. PubMed ID: 10566833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bexarotene: new preparation. Cutaneous lymphoma: too many adverse effects.
    Prescrire Int; 2004 Jun; 13(71):94-7. PubMed ID: 15233146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland.
    Väkevä L; Ranki A; Hahtola S
    Acta Derm Venereol; 2012 May; 92(3):258-63. PubMed ID: 22678563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients.
    Bouwhuis SA; Davis MD; el-Azhary RA; McEvoy MT; Gibson LE; Knudsen JM; Kist JM; Pittelkow MR
    J Am Acad Dermatol; 2005 Jun; 52(6):991-6. PubMed ID: 15928617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bexarotene--an alternative therapy for progressive cutaneous T-cell lymphoma? First experiences.
    Bohmeyer J; Stadler R; Kremer A; Nashan D; Muche M; Gellrich S; Luger T; Sterry W
    J Dtsch Dermatol Ges; 2003 Oct; 1(10):785-9. PubMed ID: 16281814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psoralen plus long-wave UV-A (PUVA) and bexarotene therapy: An effective and synergistic combined adjunct to therapy for patients with advanced cutaneous T-cell lymphoma.
    McGinnis KS; Shapiro M; Vittorio CC; Rook AH; Junkins-Hopkins JM
    Arch Dermatol; 2003 Jun; 139(6):771-5. PubMed ID: 12810509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of apoptosis of Sézary cells in the circulation following oral bexarotene therapy.
    Brennand S; Sutton VR; Biagi J; Trapani JA; Westerman D; McCormack CJ; Seymour JF; Kennedy G; Prince HM
    Br J Dermatol; 2005 Jun; 152(6):1199-205. PubMed ID: 15948982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The optimal use of bexarotene in cutaneous T-cell lymphoma.
    Gniadecki R; Assaf C; Bagot M; Dummer R; Duvic M; Knobler R; Ranki A; Schwandt P; Whittaker S
    Br J Dermatol; 2007 Sep; 157(3):433-40. PubMed ID: 17553039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bexarotene: a clinical review.
    Farol LT; Hymes KB
    Expert Rev Anticancer Ther; 2004 Apr; 4(2):180-8. PubMed ID: 15056048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.